3D Prediction of Patient-Specific Response
NCT03561207 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 570
Last updated 2023-03-24
Summary
This is a prospective, non-randomized, observational registry study evaluating a patient-specific ex vivo 3D (EV3D) assay for drug response using a patient's own biopsy or resected tumor tissue for assessing tissue response to therapy in patients with advanced cancers, including ovarian cancer, high-grade gliomas, and high-grade rare tumors.
Conditions
- Advanced Cancer
- Ovarian Cancer
- Glioblastoma Multiforme
- Anaplastic Astrocytoma
Interventions
- DIAGNOSTIC_TEST
-
EV3D Assay
The EV3D assay uses freshly obtained tumor specimen to predict tissue drug response.
Sponsors & Collaborators
-
KIYATEC
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-06-11
- Primary Completion
- 2024-06-30
- Completion
- 2024-12-31
Countries
- United States
Study Locations
More Related Trials
-
Vorinostat in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cavity Cancer
NCT00132067 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Evaluating the Safety and Pharmacokinetics of DMUC4064A in Participants With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer
NCT02146313 ·Status: COMPLETED ·Phase: PHASE1
-
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
NCT01210222 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer
NCT04092270 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer
NCT03099499 ·Status: TERMINATED ·Phase: PHASE2
-
OveRcoming immunosupprEssion aNd rebAlancing the Immune reSponSe in ovAriaN CancEr Study
NCT06611072 ·Status: RECRUITING ·Phase: NA
-
Vaccine Therapy in Treating Patients With Stage III-IV or Recurrent Ovarian Cancer
NCT01322802 ·Status: COMPLETED ·Phase: PHASE1
-
Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
NCT05920798 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Effect of 2-h Infusion of ON 01910.Na in Ovarian Cancer Patients
NCT00856791 ·Status: COMPLETED ·Phase: PHASE2
-
Genomic Profiling of the Residual Disease of Advanced-stage Ovarian Cancer After Neoadjuvant Chemotherapy
NCT03491033 ·Status: COMPLETED
-
Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)
NCT02558348 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
NCT04931342 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Lurtotecan Liposome in Treating Patients With Advanced or Recurrent Ovarian Epithelial Cancer
NCT00010179 ·Status: COMPLETED ·Phase: PHASE2
-
Association of Ex Vivo Drug Response (EVDR) and Clinical Outcome in Ovarian Cancer
NCT06068738 ·Status: TERMINATED
-
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
NCT06824467 ·Status: RECRUITING ·Phase: PHASE3
-
Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Doxorubicin)
NCT00635193 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Liposome-Encapsulated Doxorubicin Citrate With or Without Gemcitabine Hydrochloride in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
NCT01100372 ·Status: UNKNOWN ·Phase: PHASE2
-
Combination Therapy of Senaparib and Bevacizumab for First-line Maintenance Therapy in Newly Diagnosed Advanced Homologous Recombination Proficient Ovarian Cancer Based on Exosome Protein Marker
NCT07120451 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Study of EV for Recurrent Endometrial Carcinoma
NCT07139977 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Exosome-based Recurrence Score for Post-Treatment Ovarian Cancer
NCT06925126 ·Status: NOT_YET_RECRUITING
-
Ovarian Cancer Treatment With a Liposome Formulated mRNA Vaccine in Combination With (Neo-)Adjuvant Chemotherapy
NCT04163094 ·Status: TERMINATED ·Phase: PHASE1
-
A Study of the Safety and Effects of EMD 72000 in Subjects With Recurrent Ovarian Cancer
NCT00073541 ·Status: COMPLETED ·Phase: PHASE2
-
Docetaxel in Treating Patients With Recurrent or Persistent Endometrial Carcinoma (Cancer)
NCT00085332 ·Status: COMPLETED ·Phase: PHASE2
-
Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
NCT01673217 ·Status: COMPLETED ·Phase: PHASE1
-
Gemcitabine in Treating Patients With Recurrent or Refractory Cancer of the Uterus
NCT00003316 ·Status: TERMINATED ·Phase: PHASE2